Brief: Enlivex Awarded Grant To Support Clinical Development Of Allocetra In Sepsis Patients
25/05/2022 13:06
May 25 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX AWARDED ITS THIRD NON-DILUTIVE ISRAEL INNOVATION
AUTHORITY GRANT TO SUPPORT THE CLINICAL DEVELOPMENT OF ALLOCETRA
IN SEPSIS PATIENTS
Source text for Eikon: ID:nGNX1Qly8G
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment